4D Molecular Therapeutics, Inc. (FDMT): Results of Operations and Financial Condition
4D Molecular Therapeutics, Inc. (FDMT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 fdmt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones • Completed enrollment for 4D-150 4FRONT-2 wet AMD Phase 3; topline data expected in H2 2027 • 4D-150 4FRONT-1 Phase
How this was made
The 30-second read
Why it matters
Key trading inputs are updated Phase 3 topline windows (wet AMD 4FRONT-1 in Q2 2027, 4FRONT-2 in H2 2027), planned DME Phase 3 initiation in Q3 2026, and a Hercules credit facility (up to $200M, $20M initial draw) supporting funding into 2H 2028.
Market read
This is a catalyst-and-funding update for FDMT’s late-stage retinal programs, likely to affect positioning ahead of 2027 topline data and the Oct 21, 2026 Investor Day.
What to watch
The R&D expense increase and cash decline from $514.0M to $430.6M could offset optimism, and the credit facility terms (beyond initial draw) may matter for future dilution or covenants.
Background
FDMT’s 8-K (Item 2.02) reports Q2 2026 financial results and operational milestones for its lead 4D-150 program in wet AMD and DME, plus funding updates.
Ticker impact
FDMT filed an 8-K with Q2 results plus updated clinical timelines, including 4FRONT-2 enrollment completion and topline data expected in H2 2027.
Moderate upside bias into the next clinical-data milestones, with volatility around Investor Day and any subsequent trial updates.
This is a primary disclosure (8-K with financials and operational milestones) that can re-rate risk for late-stage wet AMD and DME programs, and the $200M credit facility plus $430.6M cash supports funding visibility into 2H 2028.
Market effects
Reinforces investor appetite for durable anti-VEGF delivery platforms in retinal diseases, potentially improving sentiment for similar late-stage ophthalmology programs.
Limited direct regional impact; primarily US biotech sentiment.
Global Phase 3 enrollment completion and H2 2027 topline expectations may influence broader ophthalmology trial-risk perceptions.
Counterpoint
Clinical timelines remain forward-looking; without new efficacy readouts, the market may fade the news if burn rate and dilution risk re-emerge.
Key entities
- company4D Molecular Therapeutics, Inc.
Nasdaq-listed late-stage biotech advancing 4D-150 for wet AMD and DME; reported Q2 2026 results and milestone updates in an 8-K.
- credit_facility_counterpartyHercules Capital, Inc.
Provided a strategic credit facility to FDMT for up to $200 million, with an initial $20 million draw at closing.
- collaboration_partnerOtsuka
Clinical trial cost sharing and reimbursement contributed $3.8 million in Q2 2026 collaboration and license revenue.
